Vaxxinity, Inc. (NASDAQ:VAXX – Get Rating) major shareholder United Biomedical Inc bought 18,105 shares of the business’s stock in a transaction on Tuesday, April 26th. The stock was purchased at an average price of $3.45 per share, for a total transaction of $62,462.25. Following the completion of the acquisition, the insider now owns 51,611,559 shares of the company’s stock, valued at approximately $178,059,878.55. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
VAXX stock traded up $0.16 during midday trading on Thursday, reaching $3.77. The company’s stock had a trading volume of 37,173 shares, compared to its average volume of 212,432. The company has a quick ratio of 5.61, a current ratio of 5.61 and a debt-to-equity ratio of 0.08. The company’s fifty day moving average price is $4.16. Vaxxinity, Inc. has a 1 year low of $3.04 and a 1 year high of $22.77.
Vaxxinity (NASDAQ:VAXX – Get Rating) last issued its earnings results on Thursday, March 24th. The company reported ($0.48) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.35) by ($0.13). Research analysts expect that Vaxxinity, Inc. will post -1.69 EPS for the current year.
VAXX has been the subject of several recent research reports. Evercore ISI started coverage on shares of Vaxxinity in a research report on Wednesday. They issued an “in-line” rating for the company. Zacks Investment Research lowered shares of Vaxxinity from a “hold” rating to a “sell” rating in a research report on Thursday, April 7th.
About Vaxxinity (Get Rating)
Vaxxinity, Inc, a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as dementia with Lewy Body and multiple system atrophy; and an anti-tau product candidate for various neurodegenerative conditions, including AD.
- Get a free copy of the StockNews.com research report on Vaxxinity (VAXX)
- There’s An Institutional Floor In Keurig Dr. Pepper
- Ford Falls Despite Optimistic Outlook
- Harley-Davidson Skids Into A Buying Opportunity
- Facebook (NASDAQ: FB) Soars And Wall Street Delights
- Automatic Data Processing Is Ready To Scale New Heights
Receive News & Ratings for Vaxxinity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxxinity and related companies with MarketBeat.com's FREE daily email newsletter.